GALAPAGOS NV/S (NASDAQ:GLPG) has earned a consensus recommendation of “Buy” from the eleven analysts that are covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $113.67.

A number of brokerages have recently issued reports on GLPG. ValuEngine raised GALAPAGOS NV/S from a “hold” rating to a “buy” rating in a research report on Monday, July 2nd. BidaskClub raised GALAPAGOS NV/S from a “hold” rating to a “buy” rating in a research report on Thursday, July 19th. Zacks Investment Research raised GALAPAGOS NV/S from a “hold” rating to a “buy” rating and set a $114.00 target price on the stock in a research report on Tuesday, July 17th. Cowen reaffirmed a “buy” rating on shares of GALAPAGOS NV/S in a research report on Thursday, May 31st. Finally, Stifel Nicolaus dropped their target price on GALAPAGOS NV/S from $120.00 to $109.00 and set a “buy” rating on the stock in a research report on Friday, June 29th.

Shares of GLPG opened at $112.27 on Friday. GALAPAGOS NV/S has a 12 month low of $84.13 and a 12 month high of $122.28.

GALAPAGOS NV/S (NASDAQ:GLPG) last issued its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.50) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.91) by $0.41. The company had revenue of $59.27 million for the quarter, compared to analysts’ expectations of $50.58 million. GALAPAGOS NV/S had a negative return on equity of 13.26% and a negative net margin of 70.80%. research analysts predict that GALAPAGOS NV/S will post -3.12 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in GLPG. Federated Investors Inc. PA increased its holdings in GALAPAGOS NV/S by 9.3% in the second quarter. Federated Investors Inc. PA now owns 1,424,763 shares of the biotechnology company’s stock valued at $131,335,000 after buying an additional 121,415 shares during the last quarter. Aquilo Capital Management LLC bought a new stake in GALAPAGOS NV/S in the second quarter valued at about $6,088,000. Farallon Capital Management LLC increased its holdings in GALAPAGOS NV/S by 6.3% in the first quarter. Farallon Capital Management LLC now owns 308,260 shares of the biotechnology company’s stock valued at $30,752,000 after buying an additional 18,260 shares during the last quarter. Employees Retirement System of Texas increased its holdings in GALAPAGOS NV/S by 26.8% in the second quarter. Employees Retirement System of Texas now owns 71,000 shares of the biotechnology company’s stock valued at $6,545,000 after buying an additional 15,000 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec bought a new stake in GALAPAGOS NV/S in the second quarter valued at about $1,152,000. 14.64% of the stock is owned by hedge funds and other institutional investors.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Recommended Story: What is the S&P 500 Index?

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.